American Society of Clinical Oncology technology assessment: Chemotherapy sensitivity and resistance assays
American Society of Clinical Oncology technology assessment: Chemotherapy sensitivity and resistance assays
复制标题
DOI：
10.1200/jco.2004.05.065
复制
发表时间：
2004-09-01
影响因子：
45.3
通讯作者：
Somerfield, MR
中科院分区：
文献类型：
--
作者：
Schrag, D;Garewal, HS;Somerfield, MR
目的为了开发一种技术评估的化疗敏感性和耐药性测定，以确定这些测试在常规肿瘤practice.Methods的作用，美国临床肿瘤学会（ASCO）成立了一个工作组，以开发技术评估。工作组与蓝十字和蓝盾协会技术评估中心合作。工作组制定了选择纳入ASCO评估的文章的独立标准，并开发了一个结构化的数据抽象工具，以便于对选定的手稿进行审查。一名工作组成员和一名ASCO工作人员独立审查了通过BCBSA综合文献检索和ASCO使用BCBSA检索策略（1966年至2004年1月）进行的更新文献检索确定的1，139篇摘要。在本技术评估中纳入的12篇文章中，8篇由原始BCBSA系统综述确定，1篇由行业提供，结果文献回顾没有发现任何证据基础足以支持在肿瘤学实践中使用的CSRA。建议使用化疗敏感性和耐药性测定来选择化疗药物在临床试验环境之外，不建议对个体患者使用药物。肿瘤学家应根据已发表的临床试验报告以及患者的健康状况和治疗偏好提出化疗治疗建议。由于体外分析策略具有潜在的重要性，因此参与评估这些技术的临床试验仍然是优先事项。(C)2004年，美国临床肿瘤学会。
Purpose To develop a technology assessment of chemotherapy sensitivity and resistance assays in order to define the role of these tests in routine oncology practice.Methods The American Society of Clinical Oncology (ASCO) established a Working Group to develop the technology assessment. The Working Group collaborated with the Blue Cross and Blue Shield Association (BCBSA) Technology Evaluation Center. The Working Group developed independent criteria for selecting articles for inclusion in the ASCO assessment, and developed a structured data abstraction tool to facilitate review of selected manuscripts. One Working Group member and an ASCO staff member independently reviewed the 1,139 abstracts identified by the BCBSA comprehensive literature search, and by an updated literature search performed by ASCO using the BCBSA search strategy (1966 to January 2004). Of the 12 articles included in this technology assessment, eight were identified by the original BCBSA systematic review, one was provided by industry, and three were identified by the ASCO updated literature review.Results Review of the literature does not identify any CSRAs for which the evidence base is sufficient to support use in oncology practice.Recommendations The use of chemotherapy sensitivity and resistance assays to select chemotherapeutic agents for individual patients is not recommended outside of the clinical trial setting. Oncologists should make chemotherapy treatment recommendations on the basis of published reports of clinical trials and a patient's health status and treatment preferences. Because the in vitro analytic strategy has potential importance, participation in clinical trials evaluating these technologies remains a priority. (C) 2004 by American Society of Clinical Oncology.